Greenland Mines Ltd (NASDAQ: GRML) has announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent significantly strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company indicated that the patent further supports development of its KLTO-202 program, which is targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. ALS, a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, currently has limited treatment options, making advances in gene therapy a potentially critical area of research. The Klotho protein has been associated with longevity and protection against age-related diseases, and its expression via gene therapy could offer a novel approach to slowing or halting disease progression.
Greenland Mines operates through two divisions: Mining and Biotech. The Mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Biotech division is advancing the Klotho platform, with KLTO‑202 as its primary indication for ALS. The company’s strategy involves building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
This patent grant is a key milestone for Greenland Mines’ biotech division, as it provides robust IP protection in Australia, a significant market for pharmaceutical development. The patent’s coverage of various delivery systems, including viral and non-viral methods, broadens the potential applications of the technology. Investors and stakeholders will be watching for further developments as the company progresses its KLTO-202 program through preclinical and clinical stages.
For more details on the press release, visit: https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://nnw.fm/GRML.
